Nafamostat and sepimostat identified as novel neuroprotective agents via NR2B N-methyl-D-aspartate receptor antagonism using a rat retinal excitotoxicity model

Fuwa M., Kageyama M., Ohashi K., Sasaoka M., Sato R., Tanaka M., Tashiro K.

2019
Scientific Reports

View publication

Therapeutic Area

Back of the eye (BOTE)
Categories

Preclinical development

Affiliations

Research and Development, Santen Pharmaceutical Co., Ltd, Nara, Japan; Global Alliances and External Research, Santen Pharmaceutical Co., Ltd, Nara, Japan; Department of Genomic Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan

Related Publications

Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.

Two-year prospective natural history study of EYS-associated retinitis pigmentosa using adaptive optics: the KEYS study

Masakazu H., Akiko M., Midori Y., Elena G.-S., Shohei K., Satoshi Y., Yuki T., Masanao T., Shuhei K., Yasuhiko H., Yasuo K., Kiyoko G.

Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.

View all Back of the eye (BOTE) publications